Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wanda Foltyn

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Endokrynologia Polska|April 5, 2022
Therapeutic difficulties in an aggressive ACTH-secreting pituitary adenomaWanda Foltyn
Psychiatria Polska|June 5, 2002
[Hypothalamic-pituitary-thyroid axis in depression]Wanda Foltyn, Ewa Nowakowska-Zajdel, Aleksander Danikiewicz, et al.
Endokrynologia Polska|November 10, 2011
Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncologyDariusz Kajdaniuk, Bogdan Marek, Wanda Foltyn, et al.
Endokrynologia Polska|January 23, 2013
Selected neuroendocrine tumour markers, growth factors and their receptors in typical and atypical bronchopulmonary carcinoidsAleksandra Telega, Beata Kos-Kudła, Wanda Foltyn, et al.
Endokrynologia Polska|January 17, 2019
Pernicious anaemia and endocrine glands antibodiesElżbieta Morawiec-Szymonik, Wanda Foltyn, Bogdan Marek, et al.
Neuro Endocrinology Letters|December 26, 2006
Plasma ghrelin concentrations in patients with polycystic ovary syndrome before and after 6months therapy: correlation with androgen levelsBeata Kos-Kudła, Oliwia Małecka-Mikosz, Wanda Foltyn, et al.
Endokrynologia Polska|March 2, 2012
The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomasWanda Foltyn, Janusz Strzelczyk, Bogdan Marek, et al.
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego|October 30, 2004
[Evaluation of the usefulness and effectiveness of anxiolytic therapies in neoplastic diseases]Ewa Ziółko, Jacek Knopik, Jacek Bucior, et al.
Endokrynologia Polska|November 2, 2012
The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumoursWanda Foltyn, Wojciech Zajęcki, Bogdan Marek, et al.
Polish Archives of Internal Medicine|December 10, 2019
Antibodies involved in the development of pernicious anemia and other autoimmune diseasesElżbieta Morawiec-Szymonik, Wanda Foltyn, Bogdan Marek, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Endokrynologia Polska|April 5, 2022
Therapeutic difficulties in an aggressive ACTH-secreting pituitary adenomaWanda Foltyn
Psychiatria Polska|June 5, 2002
[Hypothalamic-pituitary-thyroid axis in depression]Wanda Foltyn, Ewa Nowakowska-Zajdel, Aleksander Danikiewicz, et al.
Endokrynologia Polska|November 10, 2011
Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncologyDariusz Kajdaniuk, Bogdan Marek, Wanda Foltyn, et al.
Endokrynologia Polska|January 23, 2013
Selected neuroendocrine tumour markers, growth factors and their receptors in typical and atypical bronchopulmonary carcinoidsAleksandra Telega, Beata Kos-Kudła, Wanda Foltyn, et al.
Endokrynologia Polska|January 17, 2019
Pernicious anaemia and endocrine glands antibodiesElżbieta Morawiec-Szymonik, Wanda Foltyn, Bogdan Marek, et al.
Neuro Endocrinology Letters|December 26, 2006
Plasma ghrelin concentrations in patients with polycystic ovary syndrome before and after 6months therapy: correlation with androgen levelsBeata Kos-Kudła, Oliwia Małecka-Mikosz, Wanda Foltyn, et al.
Endokrynologia Polska|March 2, 2012
The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomasWanda Foltyn, Janusz Strzelczyk, Bogdan Marek, et al.
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego|October 30, 2004
[Evaluation of the usefulness and effectiveness of anxiolytic therapies in neoplastic diseases]Ewa Ziółko, Jacek Knopik, Jacek Bucior, et al.
Endokrynologia Polska|November 2, 2012
The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumoursWanda Foltyn, Wojciech Zajęcki, Bogdan Marek, et al.
Polish Archives of Internal Medicine|December 10, 2019
Antibodies involved in the development of pernicious anemia and other autoimmune diseasesElżbieta Morawiec-Szymonik, Wanda Foltyn, Bogdan Marek, et al.
Pageof 5